Skip to main content
. 2018 Sep 23;2018:8054073. doi: 10.1155/2018/8054073

Table 2.

Treatment groups of diabetic neuropathic pain.

Group number Group name Compound name Doses (mg/kg) Route Volume (ml/kg) Animal numbers
One-time acute treatment
1 Sham N/A N/A N/A N/A 10
2 20% PEG600/water Vehicle 0 i.p. 2 10
3 Mexiletine 30 mg/kg Mexiletine 30 p.o. gavage 2 10
4 Mexiletine 40 mg/kg Mexiletine 40 p.o. gavage 2 10a
5 Nav1.7 blocker 30 mg/kg CC4148 30 i.p. 2 10
6 Pregabalin 30 mg/kg Pregabalin 30 p.o. gavage 2 10
Chronic treatment for 8 weeks
7 Sham N/A N/A N/A N/A 15b
8 Water Vehicle 0 p.o. drinking Ad libitum 18
9 Pregabalin 30/15/20 mg/kg Pregabalin 30/15/20c p.o. drinking Ad libitum 12

aMexiletine 40 mg/kg group of rats had been dosed with Mexiletine 30 mg/kg one week prior, during week 5 to week 6 after STZ injection. bTen of the sham rats were reused from the sham group in the acute study. cPregabalin was dosed daily for 8 weeks from week 12 to week 20. Pregabalin was given at 30 mg/kg/day on day 1 and reduced to 15 mg/kg/day from day 2 onwards due to adverse side effects. After 6 weeks of treatment, the dose was increased to 20 mg/kg/day for the last two weeks of the study due to tachyphylaxis (efficacy declined with time).